These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 29453759)

  • 41. Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease.
    Perera S; Kelly D; O'Kane GM
    Curr Oncol; 2020 Nov; 27(Suppl 3):S165-S172. PubMed ID: 33343210
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Second-line Treatments of Advanced Hepatocellular Carcinoma: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Bakouny Z; Assi T; El Rassy E; Nasr F
    J Clin Gastroenterol; 2019 Apr; 53(4):251-261. PubMed ID: 30575632
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Systemic treatment for unresectable hepatocellular carcinoma.
    Leowattana W; Leowattana T; Leowattana P
    World J Gastroenterol; 2023 Mar; 29(10):1551-1568. PubMed ID: 36970588
    [TBL] [Abstract][Full Text] [Related]  

  • 44. FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib.
    Saung MT; Pelosof L; Casak S; Donoghue M; Lemery S; Yuan M; Rodriguez L; Schotland P; Chuk M; Davis G; Goldberg KB; Theoret MR; Pazdur R; Fashoyin-Aje L
    Oncologist; 2021 Sep; 26(9):797-806. PubMed ID: 33973307
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interstitial pneumonia suspected during regorafenib administration and exacerbated by subsequent therapy with lenvatinib for unresectable hepatocellular carcinoma.
    Kotani K; Enomoto M; Okada M; Yoshida K; Motoyama H; Fujii H; Hagihara A; Uchida-Kobayashi S; Morikawa H; Murakami Y; Tamori A; Kawada N
    Clin J Gastroenterol; 2019 Aug; 12(4):355-360. PubMed ID: 31020569
    [TBL] [Abstract][Full Text] [Related]  

  • 46. First-line targ veted therapies of advanced hepatocellular carcinoma: A Bayesian network analysis of randomized controlled trials.
    Ding W; Tan Y; Qian Y; Xue W; Wang Y; Jiang P; Xu X
    PLoS One; 2020; 15(3):e0229492. PubMed ID: 32134981
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A concise review of the changing landscape of hepatocellular carcinoma.
    Draper A
    Am J Manag Care; 2020 Oct; 26(10 Suppl):S211-S219. PubMed ID: 33052638
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recent Advances in Systemic Therapy for Hepatocellular Carcinoma.
    Altundag O
    Exp Clin Transplant; 2024 Jan; 22(1):3-8. PubMed ID: 35867011
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician's Choice in a New Therapeutic Scenario.
    Dipasquale A; Marinello A; Santoro A
    J Hepatocell Carcinoma; 2021; 8():241-251. PubMed ID: 33884259
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hepatocellular carcinoma, novel therapies on the horizon.
    El Dika I; Makki I; Abou-Alfa GK
    Chin Clin Oncol; 2021 Feb; 10(1):12. PubMed ID: 32527116
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges.
    Liu X; Qin S
    Oncologist; 2019 Feb; 24(Suppl 1):S3-S10. PubMed ID: 30819826
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sorafenib versus nivolumab after lenvatinib treatment failure in patients with advanced hepatocellular carcinoma.
    Kim Y; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Goh MJ; Kang W; Kim SU
    Eur J Gastroenterol Hepatol; 2023 Feb; 35(2):191-197. PubMed ID: 36574310
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systemic therapy for hepatocellular carcinoma: current status and future perspectives.
    Furuse J; Ueno M; Ikeda M
    Jpn J Clin Oncol; 2021 Aug; 51(9):1363-1371. PubMed ID: 34258616
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline.
    Gordan JD; Kennedy EB; Abou-Alfa GK; Beg MS; Brower ST; Gade TP; Goff L; Gupta S; Guy J; Harris WP; Iyer R; Jaiyesimi I; Jhawer M; Karippot A; Kaseb AO; Kelley RK; Knox JJ; Kortmansky J; Leaf A; Remak WM; Shroff RT; Sohal DPS; Taddei TH; Venepalli NK; Wilson A; Zhu AX; Rose MG
    J Clin Oncol; 2020 Dec; 38(36):4317-4345. PubMed ID: 33197225
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nivolumab for the treatment of hepatocellular carcinoma.
    Finkelmeier F; Waidmann O; Trojan J
    Expert Rev Anticancer Ther; 2018 Dec; 18(12):1169-1175. PubMed ID: 30304963
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes.
    Zhang CH; Li M; Lin YP; Gao Q
    Curr Gene Ther; 2020; 20(2):84-99. PubMed ID: 32600231
    [TBL] [Abstract][Full Text] [Related]  

  • 57. First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
    Wang L; Peng Y; Qin S; Wan X; Zeng X; Li S; Liu Q; Tan C
    PLoS One; 2023; 18(4):e0279786. PubMed ID: 37053300
    [TBL] [Abstract][Full Text] [Related]  

  • 58. First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination.
    Tella SH; Kommalapati A; Mahipal A; Jin Z
    Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740326
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
    Marisi G; Cucchetti A; Ulivi P; Canale M; Cabibbo G; Solaini L; Foschi FG; De Matteis S; Ercolani G; Valgiusti M; Frassineti GL; Scartozzi M; Casadei Gardini A
    World J Gastroenterol; 2018 Sep; 24(36):4152-4163. PubMed ID: 30271080
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Management of hepatocellular carcinoma after progression on first-line systemic treatment: defining the optimal sequencing strategy in second line and beyond.
    Amaro CP; Tam VC
    Curr Oncol; 2020 Nov; 27(Suppl 3):S173-S180. PubMed ID: 33343211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.